Product Description
EGFR Antibody [31G7] | 33-350 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human EGF Receptor purified from A431 cells was used as the immunogen for the EGFR antibody.
Research Area: Cancer, Signal Transduction
Tested Application: WB, Flow, IF, IHC-P
Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE) : 2-4 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the EGFR antibody should be determined by the researcher.
1. Digest formalin-fixed tissues with Protease at 1mg/ml PBS, pH 7.4 for 10 min at 37oC
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: 31G7
Isotype: mouse IgG2a, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: This mAb recognizes a protein of 170kDa, identified as EGFR. EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF) , Transforming Growth Factor-a (TGF-a) , Heparin-binding EGF (HB-EGF) , amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.